EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access

Neoadjuvant Osimertinib for Resectable EGFR -Mutated Non–Small Cell Lung Cancer

Jianxing He, Masahiro Tsuboi iD, Walter Weder, Ke-Neng Chen iD, Maximilian J Hochmair, Jin-Yuan Shih iD, Sung Yong Lee iD, Kang-Yun Lee iD, Nguyen Viet Nhung iD, Somcharoen Saeteng, Lunxu Liu, Ligang Xing iD und 16 weitere

Journal of Clinical Oncology · 10.09.2025 · 43 (26) · 2875-2887

DOI: 10.1200/jco-25-00883 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.09.2025. Verfasst von Jianxing He und 27 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, China State Key Laboratory of Respiratory…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Aniline Compounds, Acrylamides, Lung Neoplasms. Die Arbeit wurde bisher 108-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Adjuvant osimertinib is the standard of care for patients with resected epidermal growth factor receptor ( EGFR )–mutated non–small cell lung cancer (NSCLC). Neoadjuvant treatment could improve surgical and long-term outcomes. METHODS In this randomized, controlled, phase III study, patients with resectable, EGFR -mutated, stage II-IIIB NSCLC were randomly assigned (1:1:1) to receive neoadjuvant osimertinib (80 mg orally once daily for ≥9 weeks) plus platinum-based chemotherapy (once every 3 weeks for three cycles), osimertinib monotherapy (for ≥9 weeks), or placebo plus platinum-based chemotherapy (control), followed by surgical resection. Adjuvant osimertinib was offered to eligible patients after completion of surgery. The primary end point was major pathologic response (MPR) by blinded central pathology review. Event-free survival (EFS) was a secondary end point. RESULTS Overall, 358 patients were randomly assigned to receive osimertinib plus chemotherapy (121 patients), osimertinib monotherapy (117 patients), or placebo plus chemotherapy (120 patients). Osimertinib plus chemotherapy (MPR rate 26%) and osimertinib monotherapy (25%) demonstrated statistically significant improvement in the MPR rate versus placebo plus chemotherapy (2%), with corresponding odds ratios of 19.82 (95.002% CI, 4.60 to 85.33; P < .0001) and 19.28 (99.9% CI, 1.71 to 217.39; P < .0001), respectively. With 15% data maturity, the EFS rates at 12 months were 93%, 95%, and 83% with osimertinib plus chemotherapy, osimertinib monotherapy, and placebo plus chemotherapy, respectively. In the neoadjuvant period, grade ≥3 adverse events of any cause occurred in 36%, 13%, and 33% of patients with osimertinib plus chemotherapy, osimertinib monotherapy, and placebo plus chemotherapy, respectively. No new safety concerns were identified. CONCLUSION Neoadjuvant osimertinib with or without chemotherapy demonstrated statistically significant improvement in the MPR rate over chemotherapy alone in patients with resectable, EGFR -mutated, stage II-IIIB NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungAniline CompoundsAcrylamidesLung NeoplasmsMutationAntineoplastic Combined Chemotherapy ProtocolsHumansErbB ReceptorsFemaleNeoadjuvant TherapyMiddle AgedMaleAgedAdultDouble-Blind MethodIndolesPyrimidines

Substanzen

osimertinibAniline CompoundsAcrylamidesErbB ReceptorsEGFR protein, humanIndolesPyrimidines

Autor:innen und Institutionen

  • Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, China State Key Laboratory of Respiratory Disease & National Clinical Research Centre for Respiratory Disease,…
  • Department of Thoracic Surgery and Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
  • Department of Thoracic Surgery, University of Zurich, Thoracic Surgery, Clinic Bethanien, Zurich, Switzerland.
  • State Key Laboratory of Molecular Oncology, Beijing Key Laboratory of Carcinogenesis and Translational Research, The First Department of Thoracic Surgery, Peking University Cancer Hospital & Institute, Beijing, China.
  • Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, Austria.
  • Department of Respiratory and Critical Care Medicine, Klinik Floridsdorf, Vienna Healthcare Group, Vienna, Austria.

ORCID-Profile: Masahiro Tsuboi, Ke-Neng Chen, Jin-Yuan Shih, Sung Yong Lee, Kang-Yun Lee, Nguyen Viet Nhung, Ligang Xing, Nguyen Hoang Gia, Seong Hoon Yoon, Carlos H A Teixeira, Alex Martinez-Marti, Collin M Blakely, Yasushi Yatabe, Jamie E Chaft

Förderung

  • NCI NIH HHS

Zitieren

APA

He, J., Tsuboi, M., Weder, W., Chen, K. N., Hochmair, M. J., Shih, J. Y., Lee, S. Y., Lee, K. Y., Nhung, N. V., Saeteng, S., Liu, L., Xing, L., Gia, N. H., Murakami, S., Han, Y., Saavedra, M. P., Yoon, S. H., Teixeira, C. H. A., Escriu, C., …, & NeoADAURA Investigators (2025). Neoadjuvant Osimertinib for Resectable EGFR -Mutated Non–Small Cell Lung Cancer. Journal of Clinical Oncology, 43(26), 2875-2887. https://doi.org/10.1200/jco-25-00883

Vancouver

He J, Tsuboi M, Weder W, Chen KN, Hochmair MJ, Shih JY, et al. Neoadjuvant Osimertinib for Resectable EGFR -Mutated Non–Small Cell Lung Cancer. Journal of Clinical Oncology. 2025;43(26):2875-2887. doi:10.1200/jco-25-00883

BibTeX
@article{He2025,
  author = {He, Jianxing and Tsuboi, Masahiro and Weder, Walter and Chen, Ke-Neng and Hochmair, Maximilian J and Shih, Jin-Yuan and Lee, Sung Yong and Lee, Kang-Yun and Nhung, Nguyen Viet and Saeteng, Somcharoen and Liu, Lunxu and Xing, Ligang and Gia, Nguyen Hoang and Murakami, Shuji and Han, Yongtao and Saavedra, María Paz and Yoon, Seong Hoon and Teixeira, Carlos H A and Escriu, Carles and Martinez-Marti, Alex and Blakely, Collin M and Yatabe, Yasushi and Dacic, Sanja and Rukazenkov, Yuri and Huang, Xiangning and Dayal, Anupriya and Chaft, Jamie E and NeoADAURA Investigators, NeoADAURA Investigators},
  title = {Neoadjuvant Osimertinib for Resectable EGFR -Mutated Non–Small Cell Lung Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {26},
  pages = {2875--2887},
  doi = {10.1200/jco-25-00883}
}
Kostenlos starten →